Literature DB >> 16530701

Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis.

Heidi S Phillips1, Samir Kharbanda, Ruihuan Chen, William F Forrest, Robert H Soriano, Thomas D Wu, Anjan Misra, Janice M Nigro, Howard Colman, Liliana Soroceanu, P Mickey Williams, Zora Modrusan, Burt G Feuerstein, Ken Aldape.   

Abstract

Previously undescribed prognostic subclasses of high-grade astrocytoma are identified and discovered to resemble stages in neurogenesis. One tumor class displaying neuronal lineage markers shows longer survival, while two tumor classes enriched for neural stem cell markers display equally short survival. Poor prognosis subclasses exhibit markers either of proliferation or of angiogenesis and mesenchyme. Upon recurrence, tumors frequently shift toward the mesenchymal subclass. Chromosomal locations of genes distinguishing tumor subclass parallel DNA copy number differences between subclasses. Functional relevance of tumor subtype molecular signatures is suggested by the ability of cell line signatures to predict neurosphere growth. A robust two-gene prognostic model utilizing PTEN and DLL3 expression suggests that Akt and Notch signaling are hallmarks of poor prognosis versus better prognosis gliomas, respectively.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16530701     DOI: 10.1016/j.ccr.2006.02.019

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  1399 in total

1.  Heparan Sulfate Glycosaminoglycans in Glioblastoma Promote Tumor Invasion.

Authors:  Vy M Tran; Anna Wade; Andrew McKinney; Katharine Chen; Olle R Lindberg; Jane R Engler; Anders I Persson; Joanna J Phillips
Journal:  Mol Cancer Res       Date:  2017-08-04       Impact factor: 5.852

2.  Platelet-derived growth factor receptors differentially inform intertumoral and intratumoral heterogeneity.

Authors:  Youngmi Kim; Eunhee Kim; Qiulian Wu; Olga Guryanova; Masahiro Hitomi; Justin D Lathia; David Serwanski; Andrew E Sloan; Robert J Weil; Jeongwu Lee; Akiko Nishiyama; Shideng Bao; Anita B Hjelmeland; Jeremy N Rich
Journal:  Genes Dev       Date:  2012-06-01       Impact factor: 11.361

3.  Fibulin-3 promotes glioma growth and resistance through a novel paracrine regulation of Notch signaling.

Authors:  Bin Hu; Mohan S Nandhu; Hosung Sim; Paula A Agudelo-Garcia; Joshua C Saldivar; Claire E Dolan; Maria E Mora; Gerard J Nuovo; Susan E Cole; Mariano S Viapiano
Journal:  Cancer Res       Date:  2012-06-04       Impact factor: 12.701

Review 4.  Antiangiogenic therapy for glioblastoma: current status and future prospects.

Authors:  Tracy T Batchelor; David A Reardon; John F de Groot; Wolfgang Wick; Michael Weller
Journal:  Clin Cancer Res       Date:  2014-11-15       Impact factor: 12.531

5.  Establishing cut-off points with clinical relevance for bcl-2, cyclin D1, p16, p21, p27, p53, Sox11 and WT1 expression in glioblastoma - a short report.

Authors:  Emma Camacho-Urkaray; Jorge Santos-Juanes; Francisco Borja Gutiérrez-Corres; Beatriz García; Luis M Quirós; Isabel Guerra-Merino; José Javier Aguirre; Iván Fernández-Vega
Journal:  Cell Oncol (Dordr)       Date:  2017-12-07       Impact factor: 6.730

6.  Epigenetic Regulation of ZBTB18 Promotes Glioblastoma Progression.

Authors:  Vita Fedele; Fangping Dai; Anie P Masilamani; Dieter H Heiland; Eva Kling; Ana M Gätjens-Sanchez; Roberto Ferrarese; Leonardo Platania; Doostkam Soroush; Hyunsoo Kim; Sven Nelander; Astrid Weyerbrock; Marco Prinz; Andrea Califano; Antonio Iavarone; Markus Bredel; Maria S Carro
Journal:  Mol Cancer Res       Date:  2017-05-16       Impact factor: 5.852

7.  Nicotinamide metabolism regulates glioblastoma stem cell maintenance.

Authors:  Jinkyu Jung; Leo Jy Kim; Xiuxing Wang; Qiulian Wu; Tanwarat Sanvoranart; Christopher G Hubert; Briana C Prager; Lisa C Wallace; Xun Jin; Stephen C Mack; Jeremy N Rich
Journal:  JCI Insight       Date:  2017-05-18

8.  Activation of the NF-κB pathway by the STAT3 inhibitor JSI-124 in human glioblastoma cells.

Authors:  Braden C McFarland; G Kenneth Gray; Susan E Nozell; Suk W Hong; Etty N Benveniste
Journal:  Mol Cancer Res       Date:  2013-02-05       Impact factor: 5.852

Review 9.  Glioblastoma targeted therapy: updated approaches from recent biological insights.

Authors:  M Touat; A Idbaih; M Sanson; K L Ligon
Journal:  Ann Oncol       Date:  2017-07-01       Impact factor: 32.976

10.  Paradoxical prognostic impact of TERT promoter mutations in gliomas depends on different histological and genetic backgrounds.

Authors:  Hao You; Yao Wu; Kai Chang; Xiao Shi; Xin-Da Chen; Wei Yan; Rui Li
Journal:  CNS Neurosci Ther       Date:  2017-09-03       Impact factor: 5.243

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.